Company intelligence / Profile preview
Kanglin Biotechnology
Hangzhou, Zhejiang, Chinaorpha.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kanglin Biotechnology’s lead asset, KL003, is a lentiviral vector gene therapy delivering a functional β-globin gene for one-time treatment of beta thalassemia and sickle cell disease. In a Phase 1/2 study and investigator initiated trial, KL003 demonstrated encouraging efficacy and safety—100% efficacy in 17 patients with rapid transfusion independence. The product has received Pediatric Rare Disease Designation and Orphan Drug Designation from the US FDA. Manufacturing costs are reported to be significantly lower than other approved gene therapies. A pivotal Phase 2 trial is expected to start in 2025.
- Therapeutic areas
- HematologyNeurologyInfectious Diseases
- Modalities
- Gene therapyLentiviral vector gene therapyAAV-based gene therapyHematopoietic stem cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Kanglin Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kanglin Biotechnology.